{"id":44211,"date":"2025-10-23T20:32:24","date_gmt":"2025-10-23T12:32:24","guid":{"rendered":"https:\/\/flcube.com\/?p=44211"},"modified":"2025-10-23T20:32:25","modified_gmt":"2025-10-23T12:32:25","slug":"fosun-pharma-helsinn-partner-to-produce-fosnetupitant-for-akynzeo-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44211","title":{"rendered":"Fosun Pharma &amp; Helsinn Partner to Produce Fosnetupitant for Akynzeo in China"},"content":{"rendered":"\n<p>Fosun Pharma (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>) and the Helsinn Healthcare SA announced a strategic cooperation agreement to localize the production of the anti\u2011emetic injectable formulation <strong>fosnetupitant\/palonosetron concentrated solution for injection<\/strong>, the next\u2011generation version of the proven oral drug <strong>Akynzeo<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-highlights\"><strong>Key Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusive local manufacturing<\/strong> of fosnetupitant\/palonosetron injection in mainland China, Hong\u202fKong, and Macau.<\/li>\n\n\n\n<li><strong>Streamlined supply chain<\/strong> for a drug that has achieved <strong>National Reimbursement Drug List (NRDL)<\/strong> status since 2023.<\/li>\n\n\n\n<li><strong>Regulatory milestone<\/strong>: Marketing authorization application for the injection has been accepted by the National Medical Products Administration (NMPA).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-cooperation-agreement\"><strong>Strategic Cooperation Agreement<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Fosun Pharma &amp; Helsinn Group<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>Licensing, distribution, promotion, and local manufacturing of fosnetupitant\/palonosetron injection<\/td><\/tr><tr><td><strong>Geographic Reach<\/strong><\/td><td>Mainland China, Hong\u202fKong, Macau<\/td><\/tr><tr><td><strong>Timeline<\/strong><\/td><td>Agreement signed 22\u202fOct\u202f2025; production to commence Q4\u202f2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-background-on-akynzeo\"><strong>Background on Akynzeo<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Approved 2019<\/strong> in China; <strong>NRDL inclusion 2023<\/strong>.<\/li>\n\n\n\n<li><strong>Synergistic anti\u2011emetic<\/strong>: combines fosnetupitant (half\u2011life ~96\u202fh) with palonosetron (half\u2011life ~40\u202fh).<\/li>\n\n\n\n<li><strong>Clinical impact<\/strong>: 97.6\u202f% no\u2011rescue\u2011therapy rate for delayed chemotherapy\u2011induced nausea and vomiting (CINV).<\/li>\n\n\n\n<li><strong>Market position<\/strong>: Only oral anti\u2011emetic in China demonstrating synergistic efficacy.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-an-injectable-formulation\"><strong>Why an Injectable Formulation?<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Improved patient compliance<\/strong> in inpatient settings.<\/li>\n\n\n\n<li><strong>Rapid onset<\/strong> of action for peri\u2011operative CINV management.<\/li>\n\n\n\n<li><strong>Extended shelf life<\/strong> and easier storage compared with oral capsules.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-status\"><strong>Regulatory Status<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NMPA<\/strong> accepted marketing authorization application for the injection.<\/li>\n\n\n\n<li><strong>Clinical data<\/strong>: Phase\u202fIII trial data support safety and efficacy profile identical to oral Akynzeo.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-implications-for-oncology-supportive-care\"><strong>Implications for Oncology Supportive Care<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Enhanced access<\/strong> for Chinese oncology centers and hospitals.<\/li>\n\n\n\n<li><strong>Cost\u2011effective<\/strong> solution aligned with NRDL pricing.<\/li>\n\n\n\n<li><strong>Potential for global expansion<\/strong> as Fosun and Helsinn leverage their joint manufacturing capabilities.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h2>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fosun Pharma (SHA: 600196, HKG: 2196) and the Helsinn Healthcare SA announced a strategic cooperation&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44212,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[159,3281,893,892],"class_list":["post-44211","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-fosun-pharmaceutical","tag-helsinn-healthcare","tag-hkg-2196","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma &amp; Helsinn Partner to Produce Fosnetupitant for Akynzeo in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Fosun Pharma (SHA: 600196, HKG: 2196) and the Helsinn Group announced a strategic cooperation agreement to localize the production of the anti\u2011emetic injectable formulation fosnetupitant\/palonosetron concentrated solution for injection, the next\u2011generation version of the proven oral drug Akynzeo.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44211\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma &amp; Helsinn Partner to Produce Fosnetupitant for Akynzeo in China\" \/>\n<meta property=\"og:description\" content=\"Fosun Pharma (SHA: 600196, HKG: 2196) and the Helsinn Group announced a strategic cooperation agreement to localize the production of the anti\u2011emetic injectable formulation fosnetupitant\/palonosetron concentrated solution for injection, the next\u2011generation version of the proven oral drug Akynzeo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44211\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-23T12:32:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-23T12:32:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2306.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44211#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44211\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma &amp; Helsinn Partner to Produce Fosnetupitant for Akynzeo in China\",\"datePublished\":\"2025-10-23T12:32:24+00:00\",\"dateModified\":\"2025-10-23T12:32:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44211\"},\"wordCount\":295,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44211#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2306.webp\",\"keywords\":[\"Fosun Pharmaceutical\",\"Helsinn Healthcare\",\"HKG: 2196\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44211#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44211\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44211\",\"name\":\"Fosun Pharma &amp; Helsinn Partner to Produce Fosnetupitant for Akynzeo in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44211#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44211#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2306.webp\",\"datePublished\":\"2025-10-23T12:32:24+00:00\",\"dateModified\":\"2025-10-23T12:32:25+00:00\",\"description\":\"Fosun Pharma (SHA: 600196, HKG: 2196) and the Helsinn Group announced a strategic cooperation agreement to localize the production of the anti\u2011emetic injectable formulation fosnetupitant\\\/palonosetron concentrated solution for injection, the next\u2011generation version of the proven oral drug Akynzeo.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44211#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44211\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44211#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2306.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2306.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma & Helsinn Partner to Produce Fosnetupitant for Akynzeo in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44211#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma &amp; Helsinn Partner to Produce Fosnetupitant for Akynzeo in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma &amp; Helsinn Partner to Produce Fosnetupitant for Akynzeo in China - Insight, China&#039;s Pharmaceutical Industry","description":"Fosun Pharma (SHA: 600196, HKG: 2196) and the Helsinn Group announced a strategic cooperation agreement to localize the production of the anti\u2011emetic injectable formulation fosnetupitant\/palonosetron concentrated solution for injection, the next\u2011generation version of the proven oral drug Akynzeo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44211","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma &amp; Helsinn Partner to Produce Fosnetupitant for Akynzeo in China","og_description":"Fosun Pharma (SHA: 600196, HKG: 2196) and the Helsinn Group announced a strategic cooperation agreement to localize the production of the anti\u2011emetic injectable formulation fosnetupitant\/palonosetron concentrated solution for injection, the next\u2011generation version of the proven oral drug Akynzeo.","og_url":"https:\/\/flcube.com\/?p=44211","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-23T12:32:24+00:00","article_modified_time":"2025-10-23T12:32:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2306.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44211#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44211"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma &amp; Helsinn Partner to Produce Fosnetupitant for Akynzeo in China","datePublished":"2025-10-23T12:32:24+00:00","dateModified":"2025-10-23T12:32:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44211"},"wordCount":295,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44211#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2306.webp","keywords":["Fosun Pharmaceutical","Helsinn Healthcare","HKG: 2196","SHA: 600196"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44211#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44211","url":"https:\/\/flcube.com\/?p=44211","name":"Fosun Pharma &amp; Helsinn Partner to Produce Fosnetupitant for Akynzeo in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44211#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44211#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2306.webp","datePublished":"2025-10-23T12:32:24+00:00","dateModified":"2025-10-23T12:32:25+00:00","description":"Fosun Pharma (SHA: 600196, HKG: 2196) and the Helsinn Group announced a strategic cooperation agreement to localize the production of the anti\u2011emetic injectable formulation fosnetupitant\/palonosetron concentrated solution for injection, the next\u2011generation version of the proven oral drug Akynzeo.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44211#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44211"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44211#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2306.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2306.webp","width":1080,"height":608,"caption":"Fosun Pharma & Helsinn Partner to Produce Fosnetupitant for Akynzeo in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44211#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma &amp; Helsinn Partner to Produce Fosnetupitant for Akynzeo in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2306.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44211"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44211\/revisions"}],"predecessor-version":[{"id":44213,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44211\/revisions\/44213"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44212"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44211"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44211"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}